Qlife Holding AB (QLIFE) - Total Liabilities
Based on the latest financial reports, Qlife Holding AB (QLIFE) has total liabilities worth Skr17.14 Million SEK (≈ $1.84 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore QLIFE cash flow metrics to assess how effectively this company generates cash.
Qlife Holding AB - Total Liabilities Trend (2019–2025)
This chart illustrates how Qlife Holding AB's total liabilities have evolved over time, based on quarterly financial data. Check Qlife Holding AB (QLIFE) asset resilience to evaluate the company's liquid asset resilience ratio.
Qlife Holding AB Competitors by Total Liabilities
The table below lists competitors of Qlife Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RevoluGROUP Canada Inc
V:REVO
|
Canada | CA$1.11 Million |
|
TFP Solutions Bhd
KLSE:0145
|
Malaysia | RM6.57 Million |
|
Chatham Rock Phosphate Ltd
V:NZP
|
Canada | CA$587.59K |
|
Real Estate Credit Investments Limited
LSE:RECI
|
UK | GBX117.51 Million |
|
Victorian Plumbing Group PLC
LSE:VIC
|
UK | GBX107.80 Million |
|
Comanche International Public Company Limited
BK:COMAN
|
Thailand | ฿14.00 Million |
|
iCoreConnect Inc. Common stock
NASDAQ:ICCT
|
USA | $17.24 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Qlife Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see QLIFE market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qlife Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qlife Holding AB (2019–2025)
The table below shows the annual total liabilities of Qlife Holding AB from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.14 Million ≈ $1.84 Million |
+31.18% |
| 2024-12-31 | Skr13.07 Million ≈ $1.41 Million |
-78.98% |
| 2023-12-31 | Skr62.17 Million ≈ $6.69 Million |
-38.75% |
| 2022-12-31 | Skr101.50 Million ≈ $10.92 Million |
+235.47% |
| 2021-12-31 | Skr30.26 Million ≈ $3.26 Million |
-19.62% |
| 2020-12-31 | Skr37.64 Million ≈ $4.05 Million |
+166.61% |
| 2019-12-31 | Skr14.12 Million ≈ $1.52 Million |
-- |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vit… Read more